NCT05011058 2025-07-28
NAVAL-1
Viracta Therapeutics, Inc.
Phase 2 Terminated
Clinical Trials
7 trialsNCT03397706 2025-03-20
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies
Viracta Therapeutics, Inc.
Phase 1/2 Completed
NCT05166577 2025-03-12
Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
Viracta Therapeutics, Inc.
Phase 1 Terminated
NCT01972035 2022-04-12
ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
University of Minnesota
Phase 2 Completed
NCT03296553 2022-01-27
Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.
National Institute of Cancerología
Phase 2 Completed
NCT01441063 2020-10-27
Tocilizumab for KSHV-Associated Multicentric Castleman Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00096538 2015-11-25
Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma
Memorial Sloan Kettering Cancer Center
Phase NA Completed